Viridian Therapeutics, Inc. develops treatments for patients suffering from serious diseases.It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED) The company was founded in 2006 and is headquartered in Waltham, Massachusetts.